On July 3, 2023, IGM Biosciences, Inc. (IGM), a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, autoimmune and inflammatory diseases, and infectious diseases, announced the closing of its previously announced upsized underwritten public offering of 1,597,827 shares of its voting common stock and 9,000,000 shares of its non-voting common stock and including the full exercise of the underwriters' option to purchase 1,589,673 shares of its voting common stock, at a public offering price of $8.00 per share. Wilson Sonsini Goodrich & Rosati advised IGM on the transaction.

Concurrent with the public offering, IGM announced it closed the sale of 2,812,500 shares of its non-voting common stock in a private placement exempt from the registration requirements of the Securities Act of 1933 to certain institutional and other accredited investors affiliated with or managed by Redmile Group, LLC at a sale price equal to $8.00 per share.

BofA Securities, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers for the public offering.

The Wilson Sonsini team that advised IGM in the offering included:

Corporate
Tony Jeffries
Jennifer Knapp
James Babikian
Zach Lenox
Tyler Kivley
Joan Moses

For more information, please see IGM's news release.